Trials / Completed
CompletedNCT03413319
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-8E12 | Solution for infusion |
Timeline
- Start date
- 2018-04-17
- Primary completion
- 2019-11-20
- Completion
- 2019-11-20
- First posted
- 2018-01-29
- Last updated
- 2019-12-03
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03413319. Inclusion in this directory is not an endorsement.